Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy

JAMA Neurol. 2017 Apr 1;74(4):482-483. doi: 10.1001/jamaneurol.2016.5936.

Authors

Valentina Damato¹, Amelia Evoli¹, Raffaele Iorio²

Affiliations

¹ Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy.
² Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy2Don Gnocchi ONLUS Foundation, Milan, Italy.

PMID: 28166310
DOI: 10.1001/jamaneurol.2016.5936

No abstract available

Publication types

Comment

MeSH terms

Humans
Immunologic Factors
Neuromyelitis Optica*
Rituximab*

Substances

Immunologic Factors
Rituximab